Despite all of their promise, newer medicines, especially those based on advanced technologies, have been met with unprecedented challenges in scaling up manufacturing, quality control and commercial launch.
Hear how developers have approached different aspects of the manufacturing process to bring new and innovative treatments to patients.
C. Greg Guyer, Ph.D., chief technical officer and executive vice president of global manufacturing and technical operations, BioMarin
Sierk Poetting, Ph.D., chief operating officer, BioNTech
Matthew Herper, senior writer, editorial director of events, STAT (moderator)